SEC Form SC14D9C filed by LAVA Therapeutics N.V.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934
(Amendment No. )
LAVA Therapeutics N.V.
(Name of Subject Company)
LAVA Therapeutics N.V.
(Name of Persons Filing Statement)
Common shares, nominal value €0.12 per share
(Title of Class of Securities)
N51517105
(CUSIP Number of Class of Securities)
Stephen Hurly
Chief Executive Officer and President
LAVA Therapeutics N.V.
Yalelaan 62
3584 CM Utrecht, The Netherlands
+31 85 016 3100
(Name, address, and telephone number of person authorized to receive notices and communications
on behalf of the persons filing statement)
With a copy to:
Divakar Gupta
Katie Kazem
Courtney T. Thorne
Rita Sobral
Cooley LLP
55 Hudson Yards
New York, New York 10001
+1 (212) 479-6000
| x | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
This Schedule 14D-9 filing consists of the following communication related to the proposed acquisition of LAVA Therapeutics N.V., a public limited liability company (naamloze vennootschap) organized under the laws of The Netherlands (the “Company”), pursuant to the terms of a Share Purchase Agreement, dated as of August 3, 2025, by and among the Company and XOMA Royalty Corporation, a Nevada corporation:
| · | Press Release of XOMA Realty Corporation and LAVA Therapeutics N.V. dated August 4, 2025 (Exhibit 99.1) |
I-1